Enhancing the Extraordinary
Our Story
Founder's Vision
Lyell Founder and Board Chair Rick Klausner, M.D., shares his vision for conquering oncology’s unfinished business.
Our Science
Technology designed to generate CAR T cells that deliver more durable outcomes for patients with cancer.
Our Pipeline
Our pipeline targets hematologic malignancies and solid tumors with significant unmet medical need.
Dedicated to Patients
An unwavering focus on science guides our mission to deliver transformative CAR T-cell therapies for patients with solid tumors and hematologic malignancies.
Learn MoreLatest News
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3 rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2 nd line by early 2026 Presenting additional data from the ongoing Phase 1-2 trial in 3 rd line+ setting and initial clinical
View All NewsJoin Our Team
At Lyell, we are driven by our mission and focused on developing transformative therapies to improve the lives of patients.
Join our team of ambitious Lyellites who are committed to defeating cancer through innovation.
See Open Positions